Estimate and forecast cystic fibrosis population.
By Casey Godbout, Lead Epidemiologist
20 August 2014
I am the Lead Epidemiologist at Datamonitor Healthcare, based on the east coast in the US. I have a Masters in Public He...
Read full bio
Improvements in outcomes for patients with cystic fibrosis have been striking in the last 30 years, with survival rates gradually increasing. There are variations in diagnosed prevalent cases across the US and five major EU markets which can be accounted for by genetic background, precocity in diagnosis, diagnostic and selection criteria, and therapeutic approaches.
Datamonitor Healthcare has produced a 20-year epidemiology forecast using registry prevalence data to estimate and forecast the cystic fibrosis population in the US and five major EU markets between 2013 and 2033.
How will our cystic fibrosis epidemiology report benefit you?
- Recognize key drivers
Discover the factors that contribute to the epidemiology of cystic fibrosis, including genotype mutations, national screening programs, and surveillance systems through national registries, allowing you to identify what drives cystic fibrosis epidemiology.
- Identify market potential
Explore detailed forecasts of diagnosed prevalent cases of cystic fibrosis, segmented by country, age, sex, co-morbidities, mutations, and pathogens, enabling you to identify your target population and any challenges in terms of reaching them.
- Explore unmet needs
Discover selected co-morbidities associated with cystic fibrosis and the size of the affected diagnosed populations, allowing you to identify any unmet needs or problems you may face with your product.
Key questions answered
- What is the geographic distribution of cystic fibrosis in these markets and how will this change over the next 20 years?
- What are the most common co-morbidities within cystic fibrosis?
- What are the five most common genetic mutations in cystic fibrosis patients and how do these vary by country?